Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Revenue (2022 - 2025)

Historic Revenue for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to $2.0 million.

  • Taysha Gene Therapies' Revenue rose 7859.71% to $2.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 3635.91%. This contributed to the annual value of $8.3 million for FY2024, which is 4606.82% down from last year.
  • Taysha Gene Therapies' Revenue amounted to $2.0 million in Q2 2025, which was up 7859.71% from $2.3 million recorded in Q1 2025.
  • Taysha Gene Therapies' 5-year Revenue high stood at $4.7 million for Q3 2023, and its period low was -$1.3 million during Q4 2022.
  • In the last 4 years, Taysha Gene Therapies' Revenue had a median value of $2.0 million in 2024 and averaged $1.7 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Revenue soared by 80029.76% in 2023, and later crashed by 6232.62% in 2024.
  • Taysha Gene Therapies' Revenue (Quarter) stood at -$1.3 million in 2022, then skyrocketed by 376.17% to $3.6 million in 2023, then tumbled by 43.9% to $2.0 million in 2024, then dropped by 1.78% to $2.0 million in 2025.
  • Its Revenue was $2.0 million in Q2 2025, compared to $2.3 million in Q1 2025 and $2.0 million in Q4 2024.